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ABSTRACT 
Background and aims 
We sought to use PCR followed by high-resolution melting (HRM) analysis to 
develop a single closed-tube screening panel to screen for Lynch Syndrome. This 
comprises tests for microsatellite instability (MSI), MLH1 methylation promoter and 
BRAF mutation. 
Methods 
For MSI-testing, 5 mononucleotide markers (BAT25, BAT26, BCAT25, MYB, 
EWSR1) were developed. In addition, primers were designed to interrogate Region 
C of the MLH1 promoter for methylation (using bisulphite-modified DNA) and to test 
for mutations in codon 600 of BRAF. Two separate cohorts from Nottingham (n = 99, 
46 with MSI, 53 being microsatellite stable (MSS)) and Edinburgh (n=88, 45 MSI, 43 
MSS).  
Results 
All the cases (n=187) were blind tested for MSI and all were correctly characterised 
by our panel. The MLH1 promoter and BRAF were tested only in the Nottingham 
cohort. Successful blinded analysis was performed on the MLH1 promoter in 97 
cases. All MSS cases showed a pattern of non-methylation whilst 41/44 cases with 
MSI showed full methylation. The three cases with MSI and a non-methylated 
pattern had aberrations in MSH2 and MSH6 expression. BRAF mutation was 
detected in 61% of MSI cases and 11% of MSS cases.  
Finally, 12 cases were blind screened by using the whole panel as a single test. Of 
these, 5 were identified as MSS, 4 as MSI/non-LS and 3 as MSI/possible LS. These 
results were concordant with the previous data. 
Conclusion 
We describe the Nottingham Lynch Syndrome Test (N_LyST). This is a quick simple 
cheap method for screening for Lynch Syndrome. 
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INTRODUCTION 
Colorectal cancer (CRC) is a leading causes of cancer-related mortality (1-3). Most 
CRCs arise sporadically without any antecedent family history. There are, however, 
several cancer syndromes in which development of CRC is part of the phenotypic 
spectrum (1, 2). The most common of these is Lynch Syndrome (also known as 
Hereditary Non-Polyposis Colorectal Cancer) which is responsible for 2-4% of all 
CRCs (3, 4). Patients with LS are susceptible to the development of CRCs and to the 
development of extra-colonic tumours – most notably endometrial, ovarian and small 
intestine adenocarcinomas (5, 6) 
Lynch Syndrome (LS) arises as a consequence of germline mutation in one of four 
DNA mismatch repair (MMR) genes (i.e. MLH1, PMS2, MSH2, MSH6)  (7, 8). Loss 
of any of the proteins results in loss of MMR function and an increase in the rate of 
gene mutation. One of the manifestations of this is an increase in insertion-deletion 
(indel) mutations especially at DNA microsatellites – known as microsatellite 
instability (MSI) (8, 9). Tumours arising in LS therefore usually show both loss of 
expression of at least one of the MMR proteins (i.e. dMMR) and MSI (10, 11). Thus, 
dMMR and MSI – although they are distinct phenomena, are usually regarded as 
synonymous. Conversely, proficient mismatch repair (pMMR) is considered 
synonymous with a microsatellite stable (MSS) phenotype. 
Numerous studies have shown that, due to the high risk of multiple cancers and its 
relatively high prevalence, there is a clinical and economic benefit to be gained by 
screening CRCs for LS (12-15). Whilst a definitive diagnosis of LS can only be made 
by demonstration of a germline mutation in an MMR gene, the possibility of LS can 
be inferred if a tumour is shown to be dMMR or shown to have MSI. However, 
approximately 10-15% of sporadic CRCs will also show dMMR/MSI due to somatic 
loss of MMR function (10). Epigenetic silencing of the MLH1 gene is the most 
common cause of dMMR in sporadic tumours and very rarely occurs in LS (16, 17).  
Thus sporadic tumours with dMMR/MSI can be distinguished from tumours arising in 
LS by demonstrating methylation of the MLH1 promoter. Similarly, somatic mutation 
of BRAF is common in sporadic tumours with MSI but very rarely occurs in tumours 
arising in LS (17-19).  
Guidance from the National Institute of Clinical and Healthcare Excellence (NICE) 
recommends that all CRCs should be screened for the possibility of LS (12). The 
pathway suggested involves two steps: firstly, identify cases with dMMR/MSI and 
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then filter out sporadic cases by testing for BRAF mutation and MLH1 promoter 
methylation. For the first step, testing for dMMR can be performed by 
immunohistochemistry (IHC) whilst testing for MSI involves PCR followed by 
capillary electrophoresis. For the second step, PCR followed by mutation screening 
or sequencing is required for detection of BRAF mutation. Testing for MLH1 
promoter methylation can be performed by PCR on modified DNA followed by 
sequencing or gel electrophoresis. 
This strategy uses multiple tests and requires downstream analysis of the PCR 
products on different platforms. We believed that testing could be simplified using 
High Resolution Melting (HRM) analysis. HRM is an exquisitely sensitive method for 
detecting variations in DNA sequence (20-22). It can be performed at the end of a 
PCR without needing to transfer PCR products to another tube (i.e. a closed-tube 
test). We have shown previously that HRM can be used for testing for microsatellite 
instability (23, 24), for detection of BRAF mutation (23-27) and to identify promoter 
methylation (25). Here we sought to create a single panel test in which a single PCR 
run followed by HRM can be used to screen for patients at risk of Lynch Syndrome. 
 
MATERIALS AND METHODS 
Cell lines  
CRC cell lines were kindly donated by Prof Ian Tomlinson. The cell lines DLD1, 
HCT116, RKO, LoVo, and LS1034 have previously been shown to have MSI whilst 
the cell lines SW480, SW620, HUTU80, SW837 have been shown to be 
microsatellite stable (MSS) (28). DNA was extracted from cell lines using the Qiagen 
DNeasy kit (Qiagen, UK) as per manufacturer’s instructions and adjusted to a 
concentration of 20 ng/µl. Identity of the cell lines was confirmed by mutation profiling 
as previously described (25).  
Two diploid cell lines were chosen for spiking experiments in order to perform limit of 
detection experiment. DNA extracted from HCT116 (an MSI cell line) was spiked into 
DNA extracted from SW837 (MSS), to produce mixtures of DNA containing various 
proportion of HCT116 of ≈50%; ≈25%; ≈12.5%; ≈6%; ≈3% and ≈1.5%. 
 
Primary colorectal cancers 
The Nottingham cohort  
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Ninety nine cases of CRC, which had previously been tested by 
immunohistochemistry for expression of MMR proteins, were retrieved from the 
archives of Nottingham University Hospital (NUH) Pathology Department. Of these, 
46 cases which were dMMR (and by inference had MSI). The remaining 53 cases 
were pMMR (and by inference were MSS). Access to tissues and ethics approval 
were granted by Nottingham Health Sciences Biobank which has approval as an IRB 
from North West - Greater Manchester Central Research Ethics CommitteeREC 
reference: 15/NW/0685.  
 
The Edinburgh cohort 
Eighty eight cases of CRC were retrieved form the archives of the Royal Infirmary of 
Edinburgh, Pathology Department which had previously been tested for expression 
of MMR proteins or MSI. Of these, 45 cases were dMMR/MSI and 43 cases were 
pMMR/MSS. Access to annonymised use of tissues was granted by Tissue 
Governance NHS Lothian under ethics approval number SR783. 
 
DNA extraction for formalin-fixed tissue 
DNA was also extracted from formalin-fixed paraffin-embedded (FFPE) tumour 
samples. One or two 20 μm thick sections (depending on tissue surface area) were 
cut from each block. DNA was extracted using the QIAamp DNA FFPE tissue kit 
(Qiagen Ltd, UK) following the manufacturer's protocol. All DNA samples were 
adjusted to a concentration of 20 ng/µl. 
 
Validation of immunohistochemistry as a marker of MMR deficiency  
The Nottingham cohort had been tested for expression of the MMR proteins by 
immunohistochemistry (IHC). In order to confirm that the interpretation of the IHC 
was a correct reflection of the MMR function, a group of 33 cases (15 MSI/18 MSS) 
were tested by PCR followed by capillary electrophoresis (CE). PCR and CE testing 
was performed by the Molecular Genetics Laboratory at Nottingham University 
Hospitals NHS trust using the Promega MSI System version 1.2 in accordance with 
manufacturer’s instructions. Five mononucleotide markers for MSI testing (BAT-25, 
BAT-26, NR-21, NR-24, MONO-27) (29) and two pentanucleotide markers (Penta-D, 
Penta-E) for sample identity checking, were amplified using fluorescently-labelled 
primers in a multiplex PCR. Products were analysed by capillary electrophoresis on 
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an Applied Biosystems 3130xl Genetic Analyzer (Life Technologies) using the kit 
internal lane standard. Data were analysed using GeneMapper® software. Samples 
that showed microsatellite instability at ≥2 mononucleotide loci were interpreted as 
having MSI.  
 
Identification of novel markers for MSI testing 
A total of 11 different mononucleotide repeat microsatellite loci with potential utility as 
sensitive markers of MSI were tested. Of these, two markers (BAT 25 and BAT 26) 
are established MSI markers although the primers for these loci were redesigned 
(30-33). Two markers (BCAT 25 and TYMS 26) were identified via bioinformatics 
analyses by our group (we have previously described BCAT 25 (23, 24) as a useful 
marker), two markers (EWSR1 and MONO-27) were identified from published 
research articles (34-36) and five markers (MYB, ANGEL2, TP53 (BAT34CA), 
FBXO46, and TCF4)  were identified in the SelTar database (37) 
(www.seltarbase.org). The individual markers were chosen if (i) the mononucleotide 
repeat size is >10 bases and (ii) if the published rate of mutation of the marker in 
MSI tumours (CRC and gastric cancer) is >80%. Primers were designed using a 
combination of online design tools: MFEprimers (http://mfeprimer.igenetech.com), 
UCSC in silico PCR (http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr.) and 
Reverse Complement (www.bioinformatics.org.). 
The optimum annealing temperatures of the primer pairs was ascertained as 
previously described (38). Supplementary Table 1 lists all the mononucleotide repeat 
microsatellite markers, their genomic locations, amplicon sizes, the lengths of the 
mononucleotide repeats and the ranges of optimum annealing temperature. A range 
of metrics were used in order to define the best primers including reproducibility, 
PCR efficiency and range of functioning annealing temperature.  
 
Testing for MSI using HRM analysis 
In order to test for MSI using HRM, PCR was carried out each sample on the ABI 
7500 FAST Real-Time PCR System (Applied Biosystems). Each reaction was 
carried out in a final volume of 10µl and contained 5µl of 2x Hot Shot Diamond PCR 
master mix, 0.5µl of 20x (25µM) EvaGreen dye, each primer final concentration was 
at 0.25µM and 20ng DNA template. The PCR was performed using a 3-step 
procedure: 1 cycle of (95°C/5 minutes), 45 cycles of [(95°C/10 seconds)X1; (55°C/30 
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seconds)X1;  (72°C/30)X1] and 1 cycle of (72°C/2 minutes).  HRM was performed in-
tube immediately after PCR and consisted of heating to 95°C for 15 seconds, rapid 
cooling to 60°C and maintenance at 60°C for 1 minute. This was followed by slow 
ramping up at 0.03 degrees/s to 95 °C during which fluorescent data were captured.  
The melting data were analysed following normalisation but without temperature 
shifting using the ABI HRM software v2.0. Samples were regarded as MSI if ≥2 
markers (40%) showed instability; otherwise, they were regarded as microsatellite 
stable (MSS) tumours. 
The limit of detection for MSI by both CE and HRM was tested using spiked DNA 
samples (as described above). 
 
Novel primers for BRAF testing 
We have previously designed primers for screening for BRAF mutation using the 
nested QMC-PCR protocol (26, 27). For the purposes of this protocol, which requires 
a single stage PCR, novel primers were designed specifically for detection of 
mutation at codon 600.  
 
Testing for methylation of the MLH1 promoter 
Primer design  
Bisulphite modification of DNA causes a conversion of non-methylated cytosine 
residues to uracil whilst the methyl group of the methylated cytosines protects 
against this change (and cytosines are preserved). Following PCR on bisulphite 
modified DNA, the methylated cytosines remain whilst non-methylated cytosines are 
converted to thymine residues. The sequence of methylated / non-methylated DNA 
is therefore different and can be discriminated by HRM.  
The promoter of MLH1 contains 4 CpG rich regions (labelled A – D) which are the 
targets of epigenetic modification. It is generally considered that hypermethylation of 
the CpG island in Region C is related to MLH1 silencing (39). Furthermore, it is 
reported that Region C exists in a dichotomous state i.e. all CpG residues being 
either methylated or non-methylated (39, 40) without a state of partial methylation.  
However, the exact location of Region C is not well defined and the number of 
reported CpG residues varies between 5 and 8 (39, 40). Using the publicly available 
data, we identified a part of Region C (located –46 to –111 from the transcription 
start site; NCBI sequence ID: NC_018914.2) which would contain all 8 of the 
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reported methylated CpG residues (Supplementary Figure 1). Primers were 
designed to interrogate the whole CpG island of Region C using the exactly the 
same cycling and HRM parameters as for the MSI markers. All tests (both 
sequencing and HRM) for MLH1 Region C promoter methylation were performed on 
bisulphite modified DNA. 
 
Bisulphite conversion of DNA 
In order to test for methylation of the MLH1 promoter, it was necessary to modify the 
DNA. Bisulfite conversion of 400 ng of genomic DNA from each sample was carried 
out using the EZ-DNA Methylation-Lightning™ Kit (Zymo Research, USA), according 
to the manufacturer's protocol. Optimisation of the methylation detection HRM-PCR 
assay was carried out using completely methylated or non-methylated human control 
DNA (Qiagen Ltd, UK). 
 
Sequencing of Region C of the MLH1 promoter 
In order to confirm the dichotomous methylation state of Region C, twenty CRCs (10 
pMMR, 10 dMMR) were selected from the Nottingham cohort for Sanger sequencing 
of modified DNA. PCR prior to sequencing was performed using the reverse primer 
as described above. The forward primer however was modified to include a “squirrel” 
tail to allow sequencing of short fragments as previously described (38). PCR 
products were purified using the QIAquick kit (Qiagen) and the products sent to the 
DNA sequencing facilities (School of Life Sciences, University of Nottingham) and 
sequenced using Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing Kit 
and 3130xl ABI PRISM Genetic Analyzer (Data collection software v3.0, Sequence 
analysis software v5.2). The chromatograms were interpreted using Finch TV 1.4.0 
free software from www.geospiza.com/finchtv .  
 
Evaluation of the N_LyST panel 
All the biomarkers were tested together as a single panel test. Twelve cases were 
selected from the Nottingham cohort. This selection contained five cases designated 
as MSS, four cases designated as MSI with MLH1 deficiency and three cases 
designated as MSI with deficiency of MSH2/MSH6. They were assigned a new ID 
and were tested blind.  
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Statistical analysis 
GraphPad Prism software version 5.0 was used for statistical analysis. The Chi 
squared test was used to test for association between different factors. A value of 
p<0.05 was taken as being statistically significant. 
 
RESULTS 
Validation of IHC as a marker of mismatch repair function 
The Nottingham cohort had been selected using IHC expression of MMR proteins as 
a marker of MMR function. To confirm the association between IHC data and the 
presence or MSI, 33 cases from this cohort were tested by CE for the presence of 
MSI. Of these, 15 had been designated dMMR and 18 were pMMR. There was 
100% concordance between the IHC analysis and MSI test results. 
 
Utility of HRM for detection of MSI 
From 11 different potential microsatellite loci, a panel of 5 markers comprising 
BAT25, BAT26, BCAT25, MYB and EWSR1 was chosen as the one showing the 
best performance. Our panel was compared with the commercial CE panel for their 
limit of detection for MSI calling.  Using spiked samples containing varying 
proportions of DNA from MSI/MSS cell lines, the CE method and HRM were 
comparable with a limit of detection ≈6.25% (Figure 1). 
Our panel was used to test the Nottingham cohort of 99 cases of CRC (46 dMMR 
and 53 pMMR) and both observers correctly called every case. The Edinburgh 
cohort of 88 (45 dMMR/MSI and 43 pMMR/MSS) were tested separately. The HRM 
data were analysed by the same two observers and one observer correctly called all 
cases whilst the other observer miscalled 2 case of MSI as MSS. Although we 
applied the generally used threshold of instability at ≥2 markers (40%) for a call of 
MSI, most cases usually showed instability at 4-5 markers and only one case, out of 
the total of 91 cases designated dMMR/MSI, was found to have instability at only 2 
markers. Of the cases designated as MSS, 7% (7/96) had instability at 1 marker only 
whilst the remainder did not show any alteration in the microsatellite markers.  
 
Screening for BRAF mutation 
New primers to screen for BRAF codon 600 mutation were designed and optimised 
to work as a single stage test using the cycling conditions for MSI testing. Primers 
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were optimised and tested on cell lines with known BRAF mutation status (data not 
shown). All cases in the Nottingham cohort were tested and 28/46 (61%) of cases 
designated as MSI showed mutation whilst 6/53 (11%) of the MSS cases showed 
mutation. This frequency of mutation is consistent with published data and confirm 
the significant association of MSI with BRAF mutation (chi squared test, p<0.0001). 
 
Analysis of MLH1 promoter methylation 
Sequencing of Region C 
Twenty cases of CRC form the Nottingham cohort (10 MSI, 10 MSS) were tested for 
MLH1 promoter methylation by direct sequencing. Our findings replicated published 
data with 10/10 case of MSS CRC showing conversion of all 8 of the cytosines at the 
CpG sites to thymine without any cases suggesting partial methylation (i.e. 
methylation at some residues but not others). In contrast, 10/10 cases of the MSI 
CRCs showed retention of the cytosines at the CpG sites (Figure 2). The MSI 
samples did however show a double signal at the CpG sites i.e. a cytosine and a 
thymine. Since tumour samples contain both tumour epithelium and stroma, it is 
expected that the methylated signal comes from the tumour cells whilst the signal 
from the stroma would be non-methylated. 
 
HRM analysis of Region C 
HRM was performed following PCR with primers targeted to amplify around the CpG 
island of Region C of the MLH1 promoter. Amplification, following bisulphite 
modification, of both fully methylated and fully non-methylated DNA gave a single 
peak (Figure 3A). The melting temperature (Tm) of the PCR product from the non-
methylated DNA (i.e. the “non-methylated peak”) was lower than that of PCR product 
from the methylated DNA (the “methylated peak”) reflecting the enrichment the latter 
with cytosine residues within the methylated sequence.  
 
All cases in the Nottingham cohort were tested for methylation of Region C. Two 
cases (both designated as MSI) could not be tested due to failed PCR post bisulphite 
modification of DNA.  Of the 97 successfully tested cases, two distinct melting 
patterns were seen i.e. a single peak low Tm peak (corresponding to the non-
methylated peak) and a double peak with both low and high Tm (corresponding to 
both the non-methylated peak and the methylated peak, Figure 3B). All cases 
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designated as pMMR/MSS showed only a single non-methylated peak i.e. there was 
no promoter methylation. We regard this as the “non-methylated pattern”. Of the 44 
cases with MSI, 41 showed a double peak indicating both methylated DNA and non-
methylated DNA. The double peak was associated with loss of MLH1 expression 
(Chi squared test p<0.0001) and we regard this as the “methylated pattern”. The 
double peak is mostly likely due to methylated DNA being present in the tumour 
epithelium whilst the stromal cells are likely to contain non-methylated DNA. The 
three remaining MSI cases showed a single non-methylated peak. These cases 
were deficient in MSH2 and MSH6.   
 
Screening for Lynch Syndrome using N_LyST  
In order to test the N_LyST panel, 12 cases were blind-tested in a single PCR run. 
The outcome of N_LyST is to categorise cases “probable Lynch Syndrome” if they 
show MSI, have wild-type BRAF and have a non-methylated pattern for Region C of 
the MLH1 promoter. Any other pattern would be categorised as “not Lynch 




In this paper we have described the Nottingham Lynch Syndrome Test (N_LyST) as 
a single panel closed-tube test for Lynch Syndrome screening. The cases used to 
develop this test were selected on the basis of MMR protein expression and, to 
validate the use of these cohorts for our assay, we firstly confirmed that dMMR 
based on IHC was very strongly correlated with MSI.  
N_LyST incorporates the three components of LS screening (i.e. testing for MSI, 
MLH1 promoter methylation and BRAF mutation) into a single PCR run. Firstly we 
developed a panel of five microsatellite markers which includes two established 
markers (BAT25, BAT26) and three novel markers (BCAT25, MYB and EWSR1). 
When tested in 187 CRCs (from two different institutions), there was near perfect 
concordance with the IHC/CE designation. Analysis of the HRM data was 
undertaken by two observers thereby demonstrating that the analysis is easy and 
reproducible. The HRM method has a similar limit of detection as CE analysis 
(≈6.25% mutant DNA) but CE analysis can be complicated by stutter bands that can 
cause difficulty in allele sizing (33, 41).  
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Next we designed an assay to detect mutations in codon 600 of BRAF. Reassuringly 
the detected mutation frequencies (61% in MSI tumours, 11% in MSS tumours) were 
in the expected range and the association of MSI with BRAF mutation (Chi squared 
test, p<0.0001) was seen.  
The third step was the design of an assay to test for methylation of Region C of the 
MLH1 promoter. Our sequencing and HRM data confirmed the dichotomous state of 
Region C i.e. either non-methylated or fully methylated. The HRM assay clearly 
discriminated the two states and, when tested on the Nottingham cohort, all dMMR 
cases with loss of MLH1 expression by IHC had MLH1 promoter methylation (i.e. the 
methylated pattern of two peaks) and were therefore sporadic tumours. None of the 
cases which were pMMR or dMMR due to MSH2/MSH6 loss, had MLH1 promoter 
methylation.  Finally, all components of N-LyST were put together and tested as a 
panel. Twelve cases of CRC were blind tested and perfectly categorised as “non-LS” 
or “probable LS”.  
N_LyST involves a panel of seven PCRs which are performed in a single run using a 
single cycling program. It could hugely improve workflow in a diagnostic lab since 
HRM is performed in-tube on completion of the PCR and transfer of PCR products to 
another platform for further analysis is not required. Since the test involves a panel 
applied to all tumours, it does mean that some tumours which are MSS will be 
unnecessarily tested for BRAF mutation and MLH1 promoter methylation. However, 
the cost of this is more than off-set by savings made on manpower and consumable 
due to the removal of downstream analyses of PCR products. Furthermore, since it 
is a closed-tube test, the risk of laboratory contamination with PCR products is 
eliminated.  
Most modern Real-Time PCR machines will have HRM capabilities and expensive 
specialist equipment is not required for N_LyST. The ease of the methodology and 
data interpretation mean the N-LyST could probably be performed in non-specialist 
diagnostic pathology labs. This becomes pertinent when considering that MSI testing 
is likely to increase as it provides information which extends beyond Lynch 
Syndrome testing e.g. MSI can be used to stratify patients in to groups eligible for 
treatment with 5-Fluorouracil based therapy (42, 43) or immunotherapy (44, 45). 
Such high throughput analysis will require a rapid and simple test such as N_LyST. 
An important question is whether N_LyST – since it is a screening test - is relevant in 
the era of Next Generation Sequencing (NGS). The sheer sequencing power of NGS 
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platforms would allow the MMR genes and multiple microsatellites to be sequenced 
in a single test (46). However, microsatellites regions can be problematic from some 
NGS platforms and, where there is low tumour epithelium content, great sequencing 
depth may be required. In addition, MLH1 promoter methylation testing would require 
Methyl-Seq to be performed. The economic analyses performed as part of the NICE 
guidelines concluded that it was more cost-effective to screen the tumour samples 
prior to germline sequencing (12). Since N_LyST can be performed in less time than 
that required for library preparation and sequencing with NGS, a case for including 
N_LyST in the testing pathway can be made.     
In summary, N_LyST is based on PCR and HRM and uses a panel of 7 markers to 
test for MSI, MLH1 promoter methylation and BRAF mutation in a single PCR run. It 
can be performed on most Real-time PCR machines and, as a closed-tube test, it 
can improve laboratory workflow and reduce turnaround times for testing. It is a 
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Table 1.  
 
 Mononucleotide markers      Original data 





IHC  BRAF 
1 U S U U U MSI Non-Meth WT Yes  dMMR MSH6- WT 
2 U U U E F MSI Meth M No  dMMR MLH1 - M 
3 S S S S S MSS Non-Meth WT No  pMMR  WT 
4 U U U U U MSI Meth M No  dMMR MLH1 - M 
5 S S S S S MSS Non-Meth WT No  pMMR  WT 
6 S S S S S MSS Non-Meth M No  pMMR  M 
7 S S S S S MSS Non-Meth WT No  pMMR  WT 
8 U U U U U MSI Meth M No  dMMR MLH1 - M 
9 U U U U U MSI Meth M No  dMMR MLH1- M 
10 U U U U U MSI Non-Meth WT Yes  dMMR MSH2- N/A 
11 U U U U U MSI Non-Meth WT Yes  dMMR MSH2- WT 
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FIGURE LEGENDS 
Figure 1: Limit of detection of MSI screening by HRM analysis and capillary 
electrophoresis. Cell line genomic DNA from HCT116 (MSI) was admixed with DNA 
from SW837 (MSS) to produce differing proportion of MSI/MSS DNA with calculated 
percentage MSI DNA as indicated. Figure 1A shows the analysis by HRM for each 
marker. A known MSS DNA sample was used as an internal reference standard. 
Samples containing 6.25% MSI DNA clearly show different melting pattern as 
compared to the MSS sample. Figure 1B shows the analysis of the same samples 
using capillary electrophoresis which depends on fragment size analysis. MSI is 
indicated by novel alleles of the mononucleotide markers with different sizes 
compared to the normal sample. MSI could be called in samples containing 6.25% 
MSI DNA.  
Figure 2: Sequencing of Region C of the MLH1 promoter. Region C was identified 
and Sanger sequencing (following PCR of bisulphite modified DNA) was performed 
on 10 cases of MSI CRC showing loss of MLH1 expression and MSI and 10 cases of 
MSS CRCs. Figure 2A shows a chromatogram from an MSI CRC. The sequencing 
trace shows double peaks indicating C and T residues at all eight CpG sites within 
this region (arrows). The position in relation to the transcription start site is also 
indicated. All tested MSI CRCs showed this pattern. Figure 2B is a chromatogram 
from an MSS CRC and shows a single peak (arrows) indicating a T residue at all 
eight CpG sites. All tested MSS CRCs showed this pattern and the absence of any 
double peaks would suggest that there is no partial methylation in these tumours. 
 
Figure 3:  HRM analysis of Region C of the MLH1 promoter. In order to define the 
melting patterns of methylated / non-methylated Region C of the MLH1 promoter, 
PCR was performed on fully methylated or fully non-methylated control DNA 
following bisulphite modification. Figure 3A is a derivative plot of the PCR products 
and shows that each condition (i.e. methylated or non-methylated) had a distinct 
melting peak. The melting temperature (Tm) of the methylated peak (double arrow) 
was higher than that of the non-methylated peak (single arrow) reflecting the higher 
proportion of cytosine residues within the fully methylated samples. Figure 3B shows 
the melting pattern of tumour samples which are pMMR (single arrow) and dMMR 
due to loss of MLH1 expression (double arrow). The pMMR tumours gave a single 
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non-methylated peak. The dMMR tumours gave a double peak representing a 
methylated peak (from the tumour cells) and non-methylated peak (from the stromal 
cells). All pMMR tumours tested gave a single peak and all dMMR tumours gave a 
double peak thereby reinforcing the data that this region does not have a state of 
partial methylation. 
Figure 4: Utility of the N_LyST panel to screen for Lynch Syndrome. Twelve cases 
of CRC were randomized and tested using N_LyST. Melting plots are shown for 
BCAT25 (A), BAT25 (B), BAT26 (C), MYB (D), EWSR1 (E) and BRAF (F). Derivative 
plots are shown for Region C of MLH1 (G). It can be clearly seen that the melt 
curves of the tumours with MSI are different from those with MSS. If any marker in a 
tumour with MSI is stable, it will usually melt in the same way as the markers in the 
MSS tumours. In D there is one case with MSI (asterisked) which melted differently 
from the rest of the MSS category but also clustered independently from the other six 
MSI cases, hence this was called equivocal. F shows that the melt curves of the 
tumours with wild type BRAF are different from those with mutant BRAF. G is a 
derivative plot and tumours demonstrate two discrete melting forms: “methylated” 
comprising two melting peaks which represent methylated DNA (from tumour 
epithelium) and non-methylated DNA (from tumour stroma) or “non-methylated” 
comprising one melting peak which characterises a completely non-methylated 
tumour and stroma cell population. 
 
Table 1: Screening cancers for Lynch Syndrome using the N_LyST panel. 
Twelve cancers from the Nottingham cohort were screened blind for Lynch 
Syndrome in a single PCR run (see also Figure 4). The left hand side of the table 
shows the N_LyST data whilst the original data for these cases are given on the right 
hand side of the table. The mononucleotide markers define whether a tumour has 
microsatellite instability (MSI) or whether it is microsatellite stable (MSS). The pattern 
of MSI, non-methylated MLH1 promoter and wild-type BRAF is indicative of probable 
Lynch Syndrome whilst all other patterns indicate that Lynch Syndrome is not likely. 
From this series, three cases (shaded) were correctly identified as probable LS and 
nine as non-Lynch Syndrome (pLS = probably Lynch Syndrome, U=unstable, S = 
stable, E= equivocal, F = failed, Non-Meth = non-methylated, Meth = methylated, WT 
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= wild type, M = mutant, IHC = immunohistochemistry, dMMR = deficient mismatch 
repair, pMMR = proficient mismatch repair, MLH1- = no MLH1 expression, MSH2 = 




Supplementary Figure 1: Mapping the CpG island of Region C of the MLH1 
promotor. Using publicly available data, the CpG island of Region C (containing 8 
CpG dinucleotides reported to be invariably completely methylated when MLH1 is 
silenced by promoter methylation. The 8 CpG sites are underlined with green boxes 
and are located -46 to -111 upstream of the transcription start site (NCBI sequence 
ID: NC_018914.2). Primer attachment sites are highlighted in yellow. 
 
Supplementary Table 1: Characteristics of genomic markers selected for MSI 
testing 
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Supplementary Table 1: Characteristics of genomic markers selected for MSI testing 
Marker Genome 
location 












BCAT 25 3p22.1 CTNNB1/3’UTR Bioinformatic 
analysis 
Unknown 100bp T25 50-600C 
BAT 25 4q12 CKIT/intron 13 Literature 96-100% 85bp T25 46-640C 
BAT 26 2p21-p16.3 MSH2/intron 5 Literature 92.5-100% 77bp A26 45-650C 
ANGEL2 1q32.3 ANGEL2/transcribed 
pseudogene 
www.seltarbase.org 97.8% 65bp T17 45-650C 
EWSR1 22q12.2 EWSR1/3’UTR Literature 99.5% 70bp T16 45-600C 
FBXO46 19q13.32 FBXO46/3’UTR www.seltarbase.org 95-100% 57bp T13 45-650C 
TP53(BAT34CA) 17p13.1 TP53/3’UTR www.seltarbase.org 87.5% 69bp A18 47-650C 
TCF4 18q21.2 TCF4/intronic www.seltarbase.org 83.5% 54bp T13 47-650C 
MONO27 2p22.1 MAP4K3/intron 13 Literature, 98.3% 78bp A27 55-650C 
MYB 6q23.3 MYB/intronic www.seltarbase.org 100% 75bp T23 47-650C 
TYMS26 18p11.32 TYMS/5’UTR Bioinformatic 
analysis 
Unknown 78bp A26 45-650C 
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